Sitryx’s proprietary science is supported by GSK’s drug discovery experience. The firm was founded by six researchers in the field of immunology and metabolism including Houman Ashrafian, Luke O’Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak.

In 2018, Sitryx raised $30 million series A funding from an international syndicate of investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.